Health Care

Trending Stocks Update: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Pacific Biosciences of California, Inc. (NASDAQ:PACB)

0 9

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) went higher by +1.18% to close at $ 1.72. The company exchanged total volume of 2.71 million shares throughout course of last trade however it holds an average trading capacity of 1.79 million shares. Shares of company began trading at $1.80 climbed to high of $1.82 touched the low of $1.71.

The company is trading below its 50-day moving averages of 1.80 and up from 200-day moving averages of 1.69. The firm has price to book ratio of 10.97 and its price to sale ratio was 11.50.

Arena Pharmaceuticals, Inc.’s (ARNA) has price to sale ratio of 11.64. The company gross profit margin is 63.30%. A look on the firm performance, its monthly performance is -6.52% and a quarterly performance of -5.49%. The stock price is moving up from its 20 days moving average with 0.58% and isolated negatively from 50 days moving average with -0.74%.

Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) reported that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets. The new formulation of lorcaserin will offer patients a once-a-day dosing option that may help them achieve and maintain weight loss. BELVIQ XR is predictable to be accessible in the fall of 2016. In connection with the authorization , Arena will receive a $10 million milestone payment.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. 1 Month Ago,  shares have been suggested as “BUY” from “3” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “2.5” brokerage firms. “1” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) dropped -3.12% and closed the trade at $ 7.76. The company recorded a trading capacity of 951.67 thousand shares below its three months average daily volume of 1.84 million shares. During the last trade, shares reached to high price of $8.09 and touched the low price of $7.72. The stock’s 50-day moving average is noted at $8.45 and its 200-day moving average is stands at $9.31.

Additionally, the company has EPS of -0.40. The company has market capitalization of $676.42M.

The average true range of Pacific Biosciences of California, Inc.’s (PACB) is recorded at 0.40 and the relative strength index of the stock stands 42.24. The stock price is going above to its 52 week low with 116.76% and lagging behind from its 52 week high with -44.57%. Analyst recommendation for this stock stands at 1.90. A look on the firm performance, its monthly performance is -10.19% and a quarterly performance of -10.60%. The stock price is trading downbeat from its 200 days moving average with -15.75% and down from 50 days moving average with -10.72%.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. 1 Month Ago,  shares have been suggested as “BUY” from “1” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1.5” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

 

 

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter